Roula Tsonaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4055401/publications.pdf

Version: 2024-02-01

50 978 16 28 papers citations h-index g-index

50 50 50 1585 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. American Journal of Ophthalmology, 2022, 233, 101-110.	1.7	44
2	Huntington Disease Gene Expression Signatures in Blood Compared to Brain of YAC128 Mice as Candidates for Monitoring of Pathology. Molecular Neurobiology, 2022, 59, 2532-2551.	1.9	1
3	EFFICACY OF HALF-DOSE PHOTODYNAMIC THERAPY VERSUS HIGH-DENSITY SUBTHRESHOLD MICROPULSE LASER FOR TREATING PIGMENT EPITHELIAL DETACHMENTS IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2022, 42, 721-729.	1.0	7
4	Sbk2, a Newly Discovered Atrium-Enriched Regulator of Sarcomere Integrity. Circulation Research, 2022, 131, 24-41.	2.0	5
5	Negative Binomial mixed models estimated with the maximum likelihood method can be used for longitudinal RNAseq data. Briefings in Bioinformatics, 2021, 22, .	3. 2	4
6	Biventricular function in exercise during autonomic (thoracic epidural) block. European Journal of Applied Physiology, 2021, 121, 1405-1418.	1.2	3
7	Longâ€term followâ€up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmologica, 2021, 99, 805-811.	0.6	15
8	Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients. EMBO Molecular Medicine, 2021, 13, e13328.	3.3	16
9	Pathway testing for longitudinal metabolomics. Statistics in Medicine, 2021, 40, 3053-3065.	0.8	5
10	Risk Factors for Tibial Component Loosening. Journal of Bone and Joint Surgery - Series A, 2021, 103, 1115-1124.	1.4	16
11	Home monitoring reduced short stay admissions in suspected COVID-19 patients: COVID-box project. European Respiratory Journal, 2021, 58, 2100636.	3.1	33
12	Plasma lipidomic analysis shows a disease progression signature in mdx mice. Scientific Reports, 2021, 11, 12993.	1.6	7
13	Long-term effect of $\hat{l}\pm 1$ -antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Research, 2021, 7, 00194-2021.	1.1	4
14	Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinalAand highâ€dimensional data. Statistics in Medicine, 2021, 40, 6178-6196.	0.8	3
15	RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2021, 41, 2122-2131.	1.0	8
16	Joint Modeling of Longitudinal Markers and Time-to-Event Outcomes: An Application and Tutorial in Patients After Surgical Repair of Transposition of the Great Arteries. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007593.	0.9	6
17	Expandable human cardiovascular progenitors from stem cells for regenerating mouse heart after myocardial infarction. Cardiovascular Research, 2020, 116, 545-553.	1.8	10
18	Simultaneous Enrichment Analysis of all Possible Gene-sets: Unifying Self-Contained and Competitive Methods. Briefings in Bioinformatics, 2020, 21, 1302-1312.	3.2	13

#	Article	IF	CITATIONS
19	Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11 , 505-517.	2.9	27
20	Poisson–Tweedie mixed-effects model: A flexible approach for the analysis of longitudinal RNA-seq data. Statistical Modelling, 2020, , 1471082X2093601.	0.5	4
21	Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells. Angiogenesis, 2020, 23, 699-714.	3.7	22
22	Efficacy of single versus four repeated doses of praziquantel against Schistosoma mansoni infection in school-aged children from CA'te d'Ivoire based on Kato-Katz and POC-CCA: An open-label, randomised controlled trial (RePST). PLoS Neglected Tropical Diseases, 2020, 14, e0008189.	1.3	20
23	Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models. Human Molecular Genetics, 2020, 29, 745-755.	1.4	19
24	Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial. American Journal of Ophthalmology, 2020, 216, 80-89.	1.7	30
25	Prediction of lung function and lung density of young adults who had bronchopulmonary dysplasia. ERJ Open Research, 2020, 6, 00157-2020.	1.1	4
26	Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors. Journal of Bone and Mineral Research, 2020, 37, 236-243.	3.1	9
27	Pitfalls of linear regression for estimating slopes over time and how to avoid them by using linear mixed-effects models. Nephrology Dialysis Transplantation, 2019, 34, 561-566.	0.4	23
28	Progression of aortic root dilatation and aortic valve regurgitation after the arterial switch operation. Heart, 2019, 105, 1732-1740.	1.2	47
29	Quality of Life After Curative Resection for Rectal Cancer in Patients Treated With Adjuvant Chemotherapy Compared With Observation: Results of the Randomized Phase III SCRIPT Trial. Diseases of the Colon and Rectum, 2019, 62, 711-720.	0.7	7
30	Tracking disease progression nonâ€invasively in Duchenne and Becker muscular dystrophies. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 715-726.	2.9	47
31	Crossâ€sectional serum metabolomic study of multiple forms of muscular dystrophy. Journal of Cellular and Molecular Medicine, 2018, 22, 2442-2448.	1.6	25
32	The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy., 2018, 59, 5682.		19
33	Secondary phenotype analysis in ascertained family designs: application to the Leiden longevity study. Statistics in Medicine, 2017, 36, 2288-2301.	0.8	15
34	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 327-335.	1.1	8
35	Monoamine Oxidase A (MAOA) Gene and Personality Traits from Late Adolescence through Early Adulthood: A Latent Variable Investigation. Frontiers in Psychology, 2017, 8, 1736.	1.1	12
36	Systemic complement activation in central serous chorioretinopathy. PLoS ONE, 2017, 12, e0180312.	1.1	9

3

#	Article	IF	CITATIONS
37	Community deworming alleviates geohelminth-induced immune hyporesponsiveness. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12526-12531.	3.3	58
38	Marginal Genetic Effects Estimation in Family and Twin Studies Using Random-Effects Models. Biometrics, 2015, 71, 1130-1138.	0.8	8
39	Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study. Journal of Rheumatology, 2015, 42, 1383-1391.	1.0	23
40	Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open, 2015, 1, e000041-e000041.	1.8	57
41	Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors. Annals of the Rheumatic Diseases, 2015, 74, 876-882.	0.5	11
42	Combining information from linkage and association mapping for next-generation sequencing longitudinal family data. BMC Proceedings, 2014, 8, S34.	1.8	2
43	Gene analysis for longitudinal family data using random-effects models. BMC Proceedings, 2014, 8, S88.	1.8	3
44	Estimation of genetic effects in multiple cases family studies using penalized maximum likelihood methodology. Biostatistics, 2013, 14, 220-231.	0.9	5
45	The Effect of Three-Monthly Albendazole Treatment on Malarial Parasitemia and Allergy: A Household-Based Cluster-Randomized, Double-Blind, Placebo-Controlled Trial. PLoS ONE, 2013, 8, e57899.	1.1	47
46	A twoâ€stage mixedâ€effects model approach for geneâ€set analyses in candidate gene studies. Statistics in Medicine, 2012, 31, 1190-1202.	0.8	8
47	Nonignorable Models for Intermittently Missing Categorical Longitudinal Responses. Biometrics, 2010, 66, 834-844.	0.8	13
48	A Semiâ€Parametric Shared Parameter Model to Handle Nonmonotone Nonignorable Missingness. Biometrics, 2009, 65, 81-87.	0.8	62
49	The logistic transform for bounded outcome scores. Biostatistics, 2007, 8, 72-85.	0.9	127
50	Power and sample size calculations for discrete bounded outcome scores. Statistics in Medicine, 2006, 25, 4241-4252.	0.8	7